🇺🇸 FDA
Patent

US 12240902

Anti-TREM2 antibodies and methods of use thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 12240902 (Anti-TREM2 antibodies and methods of use thereof) held by DENALI THERAPEUTICS INC. expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DENALI THERAPEUTICS INC.
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61P, A61P25/28